Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Other Operating Expenses (2020 - 2023)

Ovid Therapeutics (OVID) has disclosed Other Operating Expenses for 6 consecutive years, with -$1000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Operating Expenses fell 150.0% year-over-year to -$1000.0, compared with a TTM value of -$10000.0 through Sep 2025, down 566.64%, and an annual FY2021 reading of -$45690.0, down 111.56% over the prior year.
  • Other Operating Expenses was -$1000.0 for Q3 2025 at Ovid Therapeutics, down from $1000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $836085.0 in Q3 2022 and bottomed at -$334126.0 in Q2 2022.
  • Average Other Operating Expenses over 5 years is $46873.4, with a median of -$45.5 recorded in 2023.
  • Peak annual rise in Other Operating Expenses hit 31379.1% in 2022, while the deepest fall reached 13174.77% in 2022.
  • Year by year, Other Operating Expenses stood at $3903.0 in 2021, then surged by 21321.6% to $836085.0 in 2022, then tumbled by 99.98% to $143.0 in 2023, then tumbled by 7093.01% to -$10000.0 in 2024, then soared by 90.0% to -$1000.0 in 2025.
  • Business Quant data shows Other Operating Expenses for OVID at -$1000.0 in Q3 2025, $1000.0 in Q2 2025, and -$10000.0 in Q4 2024.